Last reviewed · How we verify
NCT06652087: SIBO-HFpEF
Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction
NA trial testing Rifaximin in Bacterial Overgrowth Syndrome Small Bowel in 40 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | I.M. Sechenov First Moscow State Medical University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 2 September 2024 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Rifaximin (rifaximin) — full drug profile →
- Standard HFpEF treatment
Conditions studied
- Bacterial Overgrowth Syndrome Small Bowel — all drugs for Bacterial Overgrowth Syndrome Small Bowel →
- Heart Failure with Preserved Ejection Fraction — all drugs for Heart Failure with Preserved Ejection Fraction →
Sponsor
I.M. Sechenov First Moscow State Medical University
Who can join
Adults 18 to 80, any sex, with Bacterial Overgrowth Syndrome Small Bowel or Heart Failure with Preserved Ejection Fraction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) (SIBO-HFpEF). The aim of the study is to evaluate the efficacy and safety of rifaximin in patients with HFpEF and SIBO.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06652087
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rifaximin
Trials testing the same drug.
- NCT07209371 — Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance · Phase 2 · recruiting
- NCT07203846 — Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor · Phase 4 · not yet recruiting
- NCT06483737 — Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) · NA · recruiting
- NCT06808009 — Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Re · NA · not yet recruiting
- NCT06518850 — Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension · Phase 1, PHASE2 · not yet recruiting
Other I.M. Sechenov First Moscow State Medical University trials
Trials by the same sponsor.
- NCT07348991 — Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG · not yet recruiting
- NCT07412457 — Guideline Adherence in Dyslipidemia With Clinical Decision Support · not yet recruiting
- NCT07396792 — Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram · not yet recruiting
- NCT07412418 — Screening for Pulmonary Embolism Using Single-channel Electrocardiogram · not yet recruiting
- NCT07518550 — Maternal and Fetal Electrocardiograms Separation Algorithm · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06652087 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by I.M. Sechenov First Moscow State Medical University
- Last refreshed: 22 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06652087.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing